MAT Biopharma

As of March 2007, MAT Biopharma initiated a Phase I/II escalating-dose study of its antibody therapeutic Ferritarg P(R) in patients with relapsed or refractory Hodgkin’s disease. The trial aimed to evaluate pharmacokinetics, safety, and maximum tolerated dose. The company received FDA Orphan Drug Designation for Ferritarg P(R) in July 2006. No recent clinical results are available. MAT Biopharma was a privately held French biopharmaceutical company focused on developing monoclonal antibody therapies targeting hematological malignancies such as Hodgkin’s lymphoma. Its lead candidate was Ferritarg P(R), which entered Phase I/II trials around March 2007 in partnership with Institut Curie after receiving FDA Orphan Drug Designation. There are no recent updates about the company's activities or pipeline progress since that time.